<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Association between Helicobacter pylori infection and duodenal ulcer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Association between Helicobacter pylori infection and duodenal ulcer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Association between Helicobacter pylori infection and duodenal ulcer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The majority of patients with duodenal ulcer (DU) are infected with <em>Helicobacter pylori</em> (<em>H. pylori</em>). However, in multicenter trials, <em>H. pylori </em>was absent in almost 30 percent of patients with an endoscopically documented duodenal ulcer [<a href="#rid1">1</a>]. Studies that have investigated these patients found that they have generally had a shorter duration of symptoms and that many had regularly used nonsteroidal anti-inflammatory drugs (NSAIDs) [<a href="#rid2">2-4</a>]. Such patients have a significantly worse outcome, especially if treated empirically for <em>H. pylori </em>infection. Thus, <em>H. pylori </em>status should be determined in all ulcer patients before initiating treatment [<a href="#rid4">4</a>]. High acid output may be a cause of recurrent DU in patients in whom <em>H. pylori </em>has been eradicated [<a href="#rid5">5</a>]. A variety of other causes are responsible for the remaining cases. (See  <a class="medical medical_review" href="/z/d/html/23.html" rel="external">"Unusual causes of peptic ulcer disease"</a>.)</p><p>The link between <em>H. pylori </em>and DU will be reviewed here. The pathophysiology of <em>H. pylori </em>infection as it relates to gastrointestinal disease in general is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15.html" rel="external">"Pathophysiology of and immune response to Helicobacter pylori infection"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EVIDENCE LINKING HELICOBACTER PYLORI TO DUODENAL ULCERS</span><span class="headingEndMark"> — </span>There are several lines of evidence that implicate <em>H. pylori </em>as a major etiologic factor in duodenal ulcers (DU):</p><p class="bulletIndent1"><span class="glyph">●</span><em>H. pylori </em>is present in most patients who have a DU that is not related to NSAID use</p><p class="bulletIndent1"><span class="glyph">●</span><em>H. pylori </em>infection is detectable before the occurrence of DU and appears to be a risk factor for the disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Eradication of <em>H. pylori </em>prevents DU recurrence</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Incidence of H. pylori in patients with duodenal ulcer</span><span class="headingEndMark"> — </span>Early studies noted a high incidence of <em>H. pylori </em>infection (then called <em>Campylobacter pylori</em>) in patients with DU [<a href="#rid6">6</a>]; subsequent reviews confirmed that <em>H. pylori </em>is detectable in 80 to 95 percent of these patients [<a href="#rid2">2,7</a>]. These data were supported by reports which found that the prevalence of <em>H. pylori </em>is negligible in populations in which ulcer disease is rare [<a href="#rid8">8</a>]. </p><p>The prevalence of <em>H. pylori </em>in patients with DU is changing in some parts of the world [<a href="#rid9">9</a>]. While <em>H. pylori </em>infection remains very common in patients from Asia with DU, it is becoming less common in patients from the United States and parts of Europe. In an epidemiologic study from China, 1030 patients underwent endoscopy and 73 percent were found to have <em>H. pylori </em>[<a href="#rid10">10</a>]. Peptic ulcers were present in 17 percent, more than two-thirds of which were duodenal ulcers. Among those with peptic ulcers, the prevalence of <em>H. pylori </em>infection was 93 percent. On the other hand, in the United States and parts of Europe, the prevalence of <em>H. pylori </em>in patients with ulcer disease appears to be falling and is now in the range of 50 to 75 percent. (See  <a class="medical medical_review" href="/z/d/html/22.html" rel="external">"Peptic ulcer disease: Epidemiology, etiology, and pathogenesis", section on 'H. pylori'</a>.)</p><p>While the association between <em>H. pylori </em>and DU is strong, it is not specific. As examples, <em>H. pylori </em>infection is also found in patients with gastric ulcers (65 to 95 percent), dyspepsia (20 to 60 percent), gastric cancer (70 to 90 percent), and asymptomatic patients (20 to 45 percent) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/20.html" rel="external">"Approach to the adult with dyspepsia"</a> and  <a class="medical medical_review" href="/z/d/html/2514.html" rel="external">"Association between Helicobacter pylori infection and gastrointestinal malignancy"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">H. pylori occurs before manifestations of the disease</span><span class="headingEndMark"> — </span>Several trials have found that preexisting <em>H. pylori </em>infection is a risk factor for the development of DU [<a href="#rid11">11-14</a>]. One study, for example, reviewed the cases of more than 5000 Native Hawaiians who had stored serum from the late 1960s [<a href="#rid12">12</a>]. Of the 65 patients who developed DU over the next 20 years, 92 percent were <em>H. pylori </em>positive versus 78 percent of controls, producing an odds ratio of 4.0. Similarly, an endoscopic study that included 526 patients with long-term follow-up found that the odds ratio of developing DU was 5.0 for those with preexisting <em>H. pylori </em>infection compared with <em>H. pylori-</em>negative subjects [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Eradication of H. pylori reduces disease recurrence</span><span class="headingEndMark"> — </span>Treatment of <em>H. pylori </em>infection in patients with DU decreases the incidence of ulcer recurrence. One meta-analysis examined the recurrence rate for DU after at least six months of follow-up. The recurrence rate was 6 percent if <em>H. pylori </em>was eradicated and 67 percent if it was not [<a href="#rid15">15</a>]. A second meta-analysis found recurrence rates of 20 and 56 percent, respectively [<a href="#rid16">16</a>]. The studies in the meta-analyses used endoscopic findings to define ulcer recurrence. It should be noted that the rate of symptomatic recurrence is lower. (See  <a class="medical medical_review" href="/z/d/html/27.html" rel="external">"Approach to refractory peptic ulcer disease"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">PATHOGENESIS OF ULCER FORMATION</span><span class="headingEndMark"> — </span>The precise mechanism by which <em>H. pylori </em>contributes to duodenal ulcer (DU) formation is incompletely understood. However, the bacterium appears to affect the following aspects of intestinal and mucosal physiology:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased gastric acid secretion</p><p class="bulletIndent1"><span class="glyph">●</span>Gastric metaplasia</p><p class="bulletIndent1"><span class="glyph">●</span>Immune response</p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal defense mechanisms</p><p></p><p>There may also be a contribution from a variety of bacterial, host, and environmental factors that have a role in the pathogenesis of ulcer formation (<a class="graphic graphic_algorithm graphicRef73521" href="/z/d/graphic/73521.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H7"><span class="h2">Increased gastric acid secretion</span><span class="headingEndMark"> — </span>Acute <em>H. pylori </em>infection induces a short period of hypochlorhydria. In contrast, chronic infection often leads to increases in basal and stimulated acid output, particularly in patients who develop DUs (<a class="graphic graphic_figure graphicRef54104" href="/z/d/graphic/54104.html" rel="external">figure 1</a>) [<a href="#rid17">17,18</a>]. In addition, following <em>H. pylori </em>eradication, mean basal and stimulated acid output drops by 50 percent at one month and returns to normal levels by one year [<a href="#rid17">17</a>].</p><p>One mechanism by which <em>H. pylori </em>may enhance gastric acid secretion is via increased release of gastrin. Gastrin is responsible for gastric acid secretion in normal subjects by two mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>It has a trophic action on parietal cells and histamine-secreting enterochromaffin-like (ECL) cells</p><p class="bulletIndent1"><span class="glyph">●</span>It stimulates parietal cells largely via the release of histamine</p><p></p><p>This process is tightly controlled by a second hormone, somatostatin, which is a potent inhibitor of gastrin synthesis, gastrin release, and gastric acid secretion. (See  <a class="medical medical_review" href="/z/d/html/33.html" rel="external">"Physiology of gastric acid secretion"</a>.)</p><p>Patients with <em>H. pylori </em>infection have elevated basal and stimulated concentrations of serum gastrin [<a href="#rid17">17,19</a>] and a decreased concentration of somatostatin [<a href="#rid20">20</a>]. The peak acid output achieved after stimulation with gastrin releasing peptide, regarded as a measure of the stomach's functional response to endogenous gastrin, is also increased threefold in healthy <em>H. pylori </em>positive patients, and sixfold in those with DU [<a href="#rid17">17,18</a>]. These values completely normalize within one year of <em>H. pylori </em>eradication (<a class="graphic graphic_figure graphicRef54104" href="/z/d/graphic/54104.html" rel="external">figure 1</a>) [<a href="#rid21">21</a>].</p><p>The peak acid output after pentagastrin stimulation (PAOPg), a measure of the functional parietal cell population, is also significantly increased in <em>H. pylori</em>-associated DU disease. However, there are conflicting data regarding the effect of <em>H. pylori </em>eradication on PAOPg [<a href="#rid17">17,22,23</a>].</p><p>The mechanism of the increased acid response in patients infected with <em>H. pylori </em>who have DU disease compared with infected healthy patients is unclear. One study suggests that it may be due to the combination of decreased sensitivity to gastrin in healthy patients, and increased maximal acid secretory capacity in those with DU [<a href="#rid24">24</a>].</p><p>Suppression of somatostatin (rather than an increase in gastrin-secreting cells) is probably the initial event that then leads to the hypergastrinemia that is evident in patients with DU and <em>H. pylori</em>. This hypothesis is supported by a study of 28 infected patients with DU that found that after the infection was successfully eradicated, the median density of somatostatin-immunoreactive cells (antral D cells) increased from 9 to 19 cells/mm muscularis mucosa, while the median somatostatin mRNA/rRNA ratio increased from 50 to 95 [<a href="#rid25">25</a>]. In contrast, the number of gastrin-immunoreactive cells and the quantity of gastrin mRNA did not change significantly. The role of <em>H. pylori </em>in this process is supported by studies that have shown eradication of infection reverses the abnormalities in gastrin and gastric acid secretion (<a class="graphic graphic_figure graphicRef54104" href="/z/d/graphic/54104.html" rel="external">figure 1</a>) [<a href="#rid17">17,22</a>].</p><p>Nevertheless, hypergastrinemia alone probably does not explain the increases in acid output in patients infected with <em>H. pylori</em>; gastrin levels often return to normal within one month after eradication, while mean basal and peak acid output remain elevated for longer periods of time. In addition, <em>H. pylori </em>itself does not appear to alter the sensitivity of gastric parietal cells to gastrin [<a href="#rid26">26</a>], although hypergastrinemia may have trophic effects over time that result in increased parietal cell mass.</p><p class="headingAnchor" id="H8"><span class="h2">Gastric metaplasia</span><span class="headingEndMark"> — </span>Gastric metaplasia refers to the presence of gastric epithelium in the first portion of the duodenum. This abnormality appears to be a response of the mucosa to excessive acid exposure since it only occurs when the luminal pH is less than 2.5 [<a href="#rid27">27</a>]. In addition to acid hypersecretion, impaired duodenal bicarbonate secretion induced by <em>H. pylori </em>also may contribute to the low duodenal luminal pH [<a href="#rid28">28</a>].</p><p>The metaplastic foci provide areas for <em>H. pylori </em>colonization, and probably have a role in the development of duodenitis. In one study, for example, 30 of 34 (88 percent) patients with active duodenitis had more than 5 percent gastric metaplasia in duodenal mucosal specimens and <em>H. pylori</em>-associated gastritis [<a href="#rid27">27</a>]. In contrast, these two factors coexisted in only 0.43 percent of patients with no duodenal inflammation. In addition, when <em>H. pylori </em>was seen histologically in duodenal biopsy specimens, it was confined only to areas of gastric metaplasia, and never occurred in the absence of a polymorphonuclear infiltrate. A more recent study confirmed that the extent of duodenal gastric metaplasia was fourfold greater in <em>H. pylori</em>-infected duodenal ulcer patients than in infected asymptomatic controls [<a href="#rid29">29</a>]. Colonization of the duodenal bulb by <em>H. pylori </em>CagA+ strains was also greater in DU patients than in infected non DU controls (80 versus 30 percent), even though prevalence of CagA+ gastric infection was similar in both groups. These studies support the contention that infection of gastric metaplasia is important in the pathogenesis on DU.</p><p><em>H. pylori </em>infection in areas of gastric metaplasia may weaken the mucosa, making it more susceptible to acid injury. This hypothesis is supported by studies which have found that gastric metaplasia increases the relative risk for ulceration fivefold; the presence of <em>H. pylori </em>within these regions increases the risk 50-fold [<a href="#rid30">30</a>].</p><p>Gastric metaplasia is not the same as gastric heterotopia, in which (presumably) congenital patches of gastric-type mucosa occur anywhere in the small or large intestine, although the two entities may be difficult to distinguish. (See  <a class="medical medical_review" href="/z/d/html/30.html" rel="external">"Metaplastic (chronic) atrophic gastritis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Immune response</span><span class="headingEndMark"> — </span>Although <em>H. pylori </em>is a noninvasive organism, it stimulates a robust inflammatory and immune response that may have a role in DU formation. The response includes increased production of inflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor alpha, and most notably, IL-8. (See  <a class="medical medical_review" href="/z/d/html/15.html" rel="external">"Pathophysiology of and immune response to Helicobacter pylori infection"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Mucosal defense factors</span><span class="headingEndMark"> — </span><em>H. pylori </em>may downregulate several important mucosal defense factors.</p><p class="bulletIndent1"><span class="glyph">●</span>Epidermal growth factor (EGF) and transforming growth factor-alpha (TGF alpha) are potent gastric acid inhibitors and stimuli of mucosal growth and protection. One study found that the basal and stimulated release of EGF is significantly increased after eradication of <em>H. pylori</em>, an effect that may play a role in ulcer healing [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with DUs have decreased proximal duodenal mucosal bicarbonate production. It is not clear if impaired bicarbonate secretion can be attributed to <em>H. pylori</em>; however, eradication of the infection does result in normalization of bicarbonate output [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>H. pylori </em>itself releases proteases that degrade normally protective mucous glycoproteins that overlie the mucosa [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Other contributing factors</span><span class="headingEndMark"> — </span>Only 10 to 15 percent of patients with <em>H. pylori </em>infection develop ulcer disease, suggesting that other factors are probably important in determining the outcome of infection. One such factor is the bacterial strain; only strains with the cytotoxin-associated gene A (cagA), coding for a 128-140 kDa protein (CagA), coexpress vacuolating cytotoxin (VacA), a toxin that causes cell injury in vitro [<a href="#rid33">33</a>]. Approximately 85 to 100 percent of patients with DU have CagA+ strains, compared with 30 to 60 percent of infected patients who do not develop ulcers [<a href="#rid34">34</a>]. However, since CagA+ strains are also associated with gastric cancer, the specificity of the association makes it less clear how the same strain can lead to two very divergent conditions. (See  <a class="medical medical_review" href="/z/d/html/15.html" rel="external">"Pathophysiology of and immune response to Helicobacter pylori infection"</a>.)</p><p>A specific<em> H. pylori </em>gene, dupA, appears to be associated with development of DU. Those infected with dupA bacteria had more intense antral inflammation, higher levels of IL-8 and less gastric atrophy, intestinal metaplasia, and gastric cancer, a cytokine and histologic profile associated with DU disease [<a href="#rid35">35</a>]. One study suggested that the dupA gene, which encompasses jhp0917 and jhp0918, was associated with an increased risk of DU and protection against gastric cancers [<a href="#rid36">36</a>]. The 112bp region of <em>H. pylori</em> dupA may be associated with an increased risk of duodenal ulcer and has the potential to serve as a biomarker for early detection of DU [<a href="#rid37">37,38</a>].</p><p>In addition, genetic factors may help determine the susceptibility to infection with <em>H. pylori </em>[<a href="#rid39">39,40</a>]. It has been suggested that patients with <em>H. pylori </em>who develop DU have an intrinsically higher parietal cell mass or sensitivity to gastrin than H. pylori-positive healthy adults [<a href="#rid24">24,30,41</a>]. This observation may explain the exaggerated acid response to various stimuli in those who develop DUs. Genetic factors may also determine duodenal cytokine response to infection. In one study, duodenal epithelial cells from patients with a duodenal ulcer had a decreased capacity to produce inflammatory cytokines compared with controls from patients without a DU [<a href="#rid42">42</a>].</p><p>Environmental factors such as smoking and nonsteroidal anti-inflammatory drug (NSAID) use may also increase the risk of ulcer formation in patients with <em>H. pylori </em>[<a href="#rid32">32,43-45</a>]. One report noted an increased prevalence of ulcers in H. pylori-infected smokers compared with infected nonsmokers (73 versus 27 percent) [<a href="#rid44">44</a>].</p><p>Multiple studies of variable design have evaluated the relationship between NSAIDs and <em>H. pylori </em>in the development of peptic ulcer disease. The following conclusions were reached in a meta-analysis of 25 such studies [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Users of NSAIDs with <em>H. pylori </em>infection were 61 times more likely to have a peptic ulcer than non-infected non-NSAID users.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Either factor alone increased the risk of ulcer disease by approximately 20-fold.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>H. pylori </em>infection and NSAID use increased the risk of ulcer bleeding by 1.8 and 4.9-fold, respectively; when present together they increased the risk of ulcer bleeding by sixfold.</p><p></p><p>A subsequent meta-analysis of studies published between 1999 and 2008 with a total of 16,080 patients found that the mean prevalence of <em>H. pylori </em>infection in DUs was 81 percent [<a href="#rid47">47</a>]. If only the last five years' literature was considered, the rate was 77 percent. <em>H. pylori</em>-negative DUs were associated with NSAID use in 21 percent of patients when studies with infection rates of less than 90 percent were examined. The majority of the <em>H. pylori-</em>negative ulcers were attributed to false-negative <em>H. pylori </em>testing, since even under optimal conditions the sensitivity of testing is below 95 percent [<a href="#rid48">48</a>]. Other causes for <em>H. pylori-</em>negative DUs were much less common.</p><p>NSAID users with a history of peptic ulcer disease should be tested and treated for <em>H. pylori </em>if they are infected; there are also data to suggest that testing and treating (if positive) all patients for <em>H. pylori </em>prior to beginning NSAID use may be warranted [<a href="#rid49">49,50</a>], although conflicting data have also been reported [<a href="#rid51">51</a>], and this is not currently the standard of care. (See  <a class="medical medical_review" href="/z/d/html/8.html" rel="external">"NSAIDs (including aspirin): Pathogenesis and risk factors for gastroduodenal toxicity"</a>.)</p><p class="headingAnchor" id="H266238396"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15735.html" rel="external">"Patient education: Peptic ulcers (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15734.html" rel="external">"Patient education: H. pylori infection (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2016.html" rel="external">"Patient education: Peptic ulcer disease (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2012.html" rel="external">"Patient education: Helicobacter pylori infection and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H100070473"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>There are several lines of evidence that implicate <em>H. pylori </em>as a major etiologic factor in duodenal ulcers (DUs) (see <a class="local">'Evidence linking Helicobacter pylori to duodenal ulcers'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>H. pylori </em>is present in most patients who have a DU that is not related to nonsteroidal anti-inflammatory drug (NSAID) use</p><p class="bulletIndent2"><span class="glyph">•</span><em>H. pylori </em>infection is detectable before the occurrence of DU and appears to be a risk factor for the disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Eradication of <em>H. pylori </em>prevents DU recurrence</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States and parts of Europe, the prevalence of <em>H. pylori </em>in patients with ulcer disease appears to be falling. It is now in the range of 50 to 75 percent but remains high in Asia. (See <a class="local">'Incidence of H. pylori in patients with duodenal ulcer'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The precise mechanism by which <em>H. pylori </em>contributes to DU formation is incompletely understood. However, the bacterium appears to affect the following aspects of intestinal and mucosal physiology which may be important (see <a class="local">'Pathogenesis of ulcer formation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased gastric acid secretion</p><p class="bulletIndent2"><span class="glyph">•</span>Gastric metaplasia</p><p class="bulletIndent2"><span class="glyph">•</span>Immune response</p><p class="bulletIndent2"><span class="glyph">•</span>Mucosal defense mechanisms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Only 10 to 15 percent of patients with <em>H. pylori </em>infection develop ulcer disease, suggesting that other factors are probably important in determining the outcome of infection. (See <a class="local">'Other contributing factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In apparent <em>H. pylori</em>-negative DUs, a thorough search for infection should be conducted as infection remains the major cause of DUs. (See <a class="local">'Other contributing factors'</a> above.)</p><p></p><p class="headingAnchor" id="H897628405"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ciociola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999; 94:1834.</a></li><li><a class="nounderline abstract_t">Tytgat G, Langenberg W, Rauws E, Rietra P. Campylobacter-like organism (CLO) in the human stomach. Gastroenterology 1985; 88:1620.</a></li><li><a class="nounderline abstract_t">McColl KE, el-Nujumi AM, Chittajallu RS, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993; 34:762.</a></li><li><a class="nounderline abstract_t">Bytzer P, Teglbjaerg PS, Danish Ulcer Study Group. Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up. Am J Gastroenterol 2001; 96:1409.</a></li><li><a class="nounderline abstract_t">Harris AW, Gummett PA, Phull PS, et al. Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output. Aliment Pharmacol Ther 1997; 11:331.</a></li><li><a class="nounderline abstract_t">Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust 1985; 142:439.</a></li><li><a class="nounderline abstract_t">Borody TJ, George LL, Brandl S, et al. Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 1991; 86:1154.</a></li><li><a class="nounderline abstract_t">Dwyer B, Sun NX, Kaldor J, et al. Antibody response to Campylobacter pylori in an ethnic group lacking peptic ulceration. Scand J Infect Dis 1988; 20:63.</a></li><li><a class="nounderline abstract_t">Kamada T, Satoh K, Itoh T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol 2021; 56:303.</a></li><li><a class="nounderline abstract_t">Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol 2010; 105:2570.</a></li><li><a class="nounderline abstract_t">Sipponen P, Varis K, Fräki O, et al. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol 1990; 25:966.</a></li><li><a class="nounderline abstract_t">Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994; 120:977.</a></li><li><a class="nounderline abstract_t">Cullen D, Collins B, Christiansen K. Long term risk of peptic ulcer disease in people with H pylori infection - A community based study. Gastroenterology 1993; 104 (Suppl):A60.</a></li><li><a class="nounderline abstract_t">Leoci C, Ierardi E, Chiloiro M, et al. Incidence and risk factors of duodenal ulcer. A retrospective cohort study. J Clin Gastroenterol 1995; 20:104.</a></li><li><a class="nounderline abstract_t">Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110:1244.</a></li><li><a class="nounderline abstract_t">Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93:1409.</a></li><li><a class="nounderline abstract_t">el-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681.</a></li><li><a class="nounderline abstract_t">el-Omar E, Penman I, Dorrian CA, et al. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 1993; 34:1060.</a></li><li><a class="nounderline abstract_t">Peterson WL, Barnett CC, Evans DJ Jr, et al. Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori. Am J Gastroenterol 1993; 88:2038.</a></li><li><a class="nounderline abstract_t">Calam J. The somatostatin-gastrin link of Helicobacter pylori infection. Ann Med 1995; 27:569.</a></li><li><a class="nounderline abstract_t">McColl KE. Helicobacter pylori: clinical aspects. J Infect 1997; 34:7.</a></li><li><a class="nounderline abstract_t">Harris AW, Gummett PA, Misiewicz JJ, Baron JH. Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Gut 1996; 38:663.</a></li><li><a class="nounderline abstract_t">Moss S, Ayesu K, Calam J. Gastrin and gastric acid output one year after eradication of Helicobacter pylori in duodenal ulcer patients. Regul Pept 1991; 35:251.</a></li><li><a class="nounderline abstract_t">Gillen D, el-Omar EM, Wirz AA, et al. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology 1998; 114:50.</a></li><li><a class="nounderline abstract_t">Moss SF, Legon S, Bishop AE, et al. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340:930.</a></li><li><a class="nounderline abstract_t">Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 1993; 34:888.</a></li><li><a class="nounderline abstract_t">Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol 1987; 40:841.</a></li><li><a class="nounderline abstract_t">Hogan DL, Rapier RC, Dreilinger A, et al. Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans. Gastroenterology 1996; 110:705.</a></li><li><a class="nounderline abstract_t">Hamlet A, Thoreson AC, Nilsson O, et al. Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. Gastroenterology 1999; 116:259.</a></li><li><a class="nounderline abstract_t">Peura DA. Ulcerogenesis: integrating the roles of Helicobacter pylori and acid secretion in duodenal ulcer. Am J Gastroenterol 1997; 92:8S.</a></li><li><a class="nounderline abstract_t">Konturek PC, Ernst H, Konturek SJ, et al. Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of Helicobacter pylori. Gut 1997; 40:463.</a></li><li class="breakAll">Isenberg J, McQuaid K, Laine L, Walsh J. Acid-Peptic Disorders. In: Textbook of Gastroenterology, 2nd ed, Yamada T (Ed), JP Lippincott, Philadelphia 1995. p.1347.</li><li><a class="nounderline abstract_t">Blaser MJ. Role of vacA and the cagA locus of Helicobacter pylori in human disease. Aliment Pharmacol Ther 1996; 10 Suppl 1:73.</a></li><li><a class="nounderline abstract_t">Weel JF, van der Hulst RW, Gerrits Y, et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis 1996; 173:1171.</a></li><li><a class="nounderline abstract_t">Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 2005; 128:833.</a></li><li><a class="nounderline abstract_t">Yamaoka Y. Roles of the plasticity regions of Helicobacter pylori in gastroduodenal pathogenesis. J Med Microbiol 2008; 57:545.</a></li><li><a class="nounderline abstract_t">Fatahi G, Talebi Bezmin Abadi A, Peerayeh SN, Forootan M. Carrying a 112 bp-segment in Helicobacter pylori dupA may associate with increased risk of duodenal ulcer. Infect Genet Evol 2019; 73:21.</a></li><li><a class="nounderline abstract_t">Akeel M, Shehata A, Elhafey A, et al. Helicobacter pylori vacA, cagA and iceA genotypes in dyspeptic patients from southwestern region, Saudi Arabia: distribution and association with clinical outcomes and histopathological changes. BMC Gastroenterol 2019; 19:16.</a></li><li><a class="nounderline abstract_t">Azuma T, Konishi J, Ito Y, et al. Genetic differences between duodenal ulcer patients who were positive or negative for Helicobacter pylori. J Clin Gastroenterol 1995; 21 Suppl 1:S151.</a></li><li><a class="nounderline abstract_t">Wu Y, Murray GK, Byrne EM, et al. GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. Nat Commun 2021; 12:1146.</a></li><li><a class="nounderline abstract_t">Graham DY. Helicobacter pylori and perturbations in acid secretion: the end of the beginning. Gastroenterology 1996; 110:1647.</a></li><li><a class="nounderline abstract_t">Strömberg E, Edebo A, Lundin BS, et al. Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors. Clin Exp Immunol 2005; 140:117.</a></li><li><a class="nounderline abstract_t">Cullen DJ, Hawkey GM, Greenwood DC, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997; 41:459.</a></li><li><a class="nounderline abstract_t">Martin DF, Montgomery E, Dobek AS, et al. Campylobacter pylori, NSAIDS, and smoking: risk factors for peptic ulcer disease. Am J Gastroenterol 1989; 84:1268.</a></li><li><a class="nounderline abstract_t">Hawkey CJ. Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut 2000; 46:310.</a></li><li><a class="nounderline abstract_t">Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30:791.</a></li><li><a class="nounderline abstract_t">McColl KE. How I manage H. pylori-negative, NSAID/aspirin-negative peptic ulcers. Am J Gastroenterol 2009; 104:190.</a></li><li><a class="nounderline abstract_t">Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350:975.</a></li><li><a class="nounderline abstract_t">Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359:9.</a></li><li><a class="nounderline abstract_t">Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352:1016.</a></li></ol></div><div id="topicVersionRevision">Topic 17 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406244" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Campylobacter-like organism (CLO) in the human stomach</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8314508" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11374675" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9146771" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recurrence of duodenal ulcer after Helicobacter pylori eradication is related to high acid output.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3982346" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pyloric Campylobacter infection and gastroduodenal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1882793" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Helicobacter pylori-negative duodenal ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3363304" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antibody response to Campylobacter pylori in an ethnic group lacking peptic ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33620586" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evidence-based clinical practice guidelines for peptic ulcer disease 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736940" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2263883" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7741826" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Helicobacter pylori infection and the risk for duodenal and gastric ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long term risk of peptic ulcer disease in people with H pylori infection - A community based study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7769187" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incidence and risk factors of duodenal ulcer. A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8613015" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732917" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7657096" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8174954" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8249971" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8541034" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The somatostatin-gastrin link of Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9120329" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Helicobacter pylori: clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8707109" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gastrin and gastric acid output one year after eradication of Helicobacter pylori in duodenal ulcer patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428218" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1357347" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8344574" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3654985" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608879" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Duodenal bicarbonate secretion: eradication of Helicobacter pylori and duodenal structure and function in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922305" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9127621" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ulcerogenesis: integrating the roles of Helicobacter pylori and acid secretion in duodenal ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176072" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176072" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mucosal expression and luminal release of epidermal and transforming growth factors in patients with duodenal ulcer before and after eradication of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730262" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Role of vacA and the cagA locus of Helicobacter pylori in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8627069" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15825067" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Duodenal ulcer promoting gene of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436586" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Roles of the plasticity regions of Helicobacter pylori in gastroduodenal pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30981881" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Carrying a 112 bp-segment in Helicobacter pylori dupA may associate with increased risk of duodenal ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30683054" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Helicobacter pylori vacA, cagA and iceA genotypes in dyspeptic patients from southwestern region, Saudi Arabia: distribution and association with clinical outcomes and histopathological changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8775009" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Genetic differences between duodenal ulcer patients who were positive or negative for Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33608531" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8613075" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Helicobacter pylori and perturbations in acid secretion: the end of the beginning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15762883" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Down-regulation of epithelial IL-8 responses in Helicobacter pylori-infected duodenal ulcer patients depends on host factors, rather than bacterial factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9391242" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2801677" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Campylobacter pylori, NSAIDS, and smoking: risk factors for peptic ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10673289" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11809181" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706147" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Review article: Helicobacter pylori-negative duodenal ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19098868" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : How I manage H. pylori-negative, NSAID/aspirin-negative peptic ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329511" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11809180" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9759744" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
